A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis

Journal of Psychopharmacology

Volumn 25, Issue 6, 2011, Pages 755-762

  Fallon, Paul ^a   Dursun, Serdar M ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antipsychotics; relapse; schizophrenia; supersensitivity psychosis; tardive dyskinesia

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; AGE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; LIFE STRESS; MALE; NATURALISTIC INQUIRY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RELAPSE; SCHIZOPHRENIA; SYMPTOM; TARDIVE DYSKINESIA;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; HUMANS; LIFE CHANGE EVENTS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; RECURRENCE; SCHIZOPHRENIA; SEX FACTORS;

EID: 79960484808     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109359097     Document Type: Article

References (58)

1. Atkins M, Burgess A, Bottomley C, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research implications. Psychiatr Bull. 1997 ; 21: 224-226 (Pubitemid 27225823)
2. Bebbington P, Wilkins S, Jones P, et al. Life events and psychosis initial results from the Camberwell Collaborative Psychosis Study. Br J Psychiatry. 1993 ; 162: 72-79 (Pubitemid 23017017)
3. Bebbington PE, Craig T, Garety P, et al. Remission and relapse in psychosis: operational definitions based on case-note data. Psychol Med. 2006 ; 36: 1551-1562 (Pubitemid 44575801)
4. Bennett J, Done J, Hunt B. Assessing the side-effects of antipsychotic drugs: a survey of CPN practice. J Psych Ment Health Nurs. 1995 ; 2: 177-182
5. Bifulco A, Brown G, Edwards A, et al Life Events and Difficulties Schedule (LEDS-2) volume 1: Life Events Manual. London: University of London: ; 1989 :
6. Bressan RA, Jones HM, Pilowsky LS. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity. J Psychopharmacol. 2004 ; 18: 124-127 (Pubitemid 38623105)
7. Brown GW, Birley JLT. Crises and life changes and the onset of schizophrenia. J Health Soc Behav. 1968 ; 9: 203-214
8. Brown GW, Carstairs M, Topping G. Post-hospital adjustment of chronic mental patients. Lancet. 1958 ; II: 685-689
9. Brown GW, Harris TO Social Origins of Depression. London: Tavistock ; 1978 :
10. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res. 1990 ; 5: 21-33
11. Chouinard G, Annable L, Ross-Chouinard A. Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull. 1986 ; 22: 891-896 (Pubitemid 17183401)
12. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008 ; 77: 69-77 (Pubitemid 351172096)
13. Chouinard G, Jones BD, Annable L. Neuroloeptic-induced supersensitivity psychosis. Am J Psychiatry. 1978 ; 135: 1409-1410
14. Chung RK, Langeluddecke P, Tennant C. Threatening life events in the onset of schizophrenia, schizophreniform psychosis and hypomania. Br J Psychiatry. 1986 ; 148: 680-685 (Pubitemid 16056791)
15. Collip D, Myin-Germeys I, Van Os J. Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia?. Schizophr Bull. 2008 ; 34: 220-225 (Pubitemid 351323342)
16. Davidson L, Schmutte T, Dinzeo T, Andres-Hyman R. Remission and recovery in schizophrenia: practitioner and patient perspectives. Schizophr Bull. 2008 ; 34: 5-8 (Pubitemid 350262290)
17. Dean CE, Kuskowski MA, Caligiuri MP. Predictors of neuroleptic-induced dyskinesia and parkinsonism. The influence of measurement methods and definition. J Clin Psychopharmacol. 2006 ; 26: 560-565 (Pubitemid 44772731)
18. Diamond BI, Borison RL. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. Psychopharmacol Bull. 1986 ; 22: 900-905 (Pubitemid 17183403)
19. Fallon P. The role of intrusive and other recent life events on symptomatology in relapses of schizophrenia: a community nursing investigation. J Psychiatr Ment Health Nurs. 2009 ; 16: 685-693
20. Foster P. Neuroleptic equivalence. Pharm J. 1989 ; 243: 431-432
21. Galili-Mosberg R, Gil-Ad A, Weizman A, Melamed E, Offen D. Haloperidol-induced neurotoxicity-possible implications for tardive dyskinesia. J Neural Transm. 2000 ; 107: 478-490
22. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rev. Washington DC: US Department of Health, Education and Welfare.
23. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contribution of psychosocial treatment. J Psychiatr Res. 1998 ; 32: 243-250 (Pubitemid 28408287)
24. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res. 2002 ; 54: 253-264 (Pubitemid 34304218)
25. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures. A WHO ten-country study. Psychol Med Suppl. 1992 ; 20: 1-7
26. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004 ; 161: 160-163 (Pubitemid 38419323)
27. Jeste DV, Lohr JB, Eastham JH, Rockwell E, Caligiuri MP. Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res. 1998 ; 32: 201-214 (Pubitemid 28408285)
28. Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand. 1983 ; 67: 339-352 (Pubitemid 13079179)
29. Kane JM. Tardive dyskinesia circa 2006. Am J Psychiatry. 2006 ; 163: 1316-1318 (Pubitemid 44464397)
30. Kent TA, Wilber RD. Reserpine withdrawal psychosis the possible role of denervation supersensitivity of receptors. J Nerv Ment Dis. 1982 ; 170: 502-504 (Pubitemid 12051657)
31. Kornhuber J, Riederer P, Reynolds GP, Beckman H, Jellinger K, Gabriel E. 3H-Spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm. 1989 ; 75: 1-10 (Pubitemid 19027066)
32. Krakowski MI, Kunz M, Czobor P, Volavka J. Long-term high-dose neuroleptic treatment: who gets it and why?. Hosp Comm Psychiatry. 1993 ; 44: 640-644 (Pubitemid 23193649)
33. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007 ; 68: 10-13 (Pubitemid 47026641)
34. Leff JP, Vaughn C. The interaction of life-events and relatives' expressed emotion in schizophrenia and depressive neurosis. Br J Psychiatry. 1980 ; 136: 146-153 (Pubitemid 10183249)
35. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Bio Psychiatry. 1999 ; 46: 729-739 (Pubitemid 29460898)
36. Lu MI, Pan JJ, Teng HW, Su KP, Shen WW. Metoclopramide-induced supersensitivity psychosis. Ann Pharmacother. 2002 ; 36: 1387-1390 (Pubitemid 34925274)
37. Margolese HC, Chouinard G, Beauclair L, Belanger MC. Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. J Clin Psychopharmacol. 2002 ; 22: 347-352 (Pubitemid 34810322)
38. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006 ; 114: 3-13 (Pubitemid 43885479)
39. Myin-Germeys L, Krabbendam PA, Delespaul AE, Van Os J. Do life events have their effect on psychosis by influencing the emotional reactivity to daily life stress?. Psychol Med. 2003 ; 33: 327-333 (Pubitemid 36221464)
40. Owen F, Crow TJ, Poulter M, Cross AJ, Longden A, Riley GJ. Increased dopamine receptor sensitivity in schizophrenia. Lancet. 1978 ; ii: 223-225 (Pubitemid 8400350)
41. Peet M, Collier J. Use of carbamazepine in psychosis after neuroleptic malignant syndrome. Br J Psychiatry. 1990 ; 156: 579-581 (Pubitemid 20116613)
42. Remington GJ, Prendergast P, Bezchlibyk-Butler KZ. Neuroleptic dosing patterns in chronic schizophrenia: a 10 year follow-up. Can J Psychiatry. 1997 ; 42: 55-57
43. Reynolds GP. Dopamine receptors and schizophrenia. Biochem Soc Trans. 1996 ; 24: 202-205 (Pubitemid 26052422)
44. Samaha AN, Seeman P, Stewart J, Kapur S. 'Breakthrough' dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007 ; 27: 2979-2986 (Pubitemid 46438984)
45. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry. 1982 ; 3: 482-495
46. Seeman P, Schwarz J, Chen J-F, et al. Psychosis pathways converge via D2 High dopamine receptors. Synapse. 2006 ; 60: 319-346 (Pubitemid 44134353)
47. Soliman A, O'Driscoll GA, Pruessner J, et al. Stress-induced dopamine release in humans at risk of psychosis: a (11 C) raclopride PET study. Neuropsychopharmocology. 2008 ; 33: 2033-2041 (Pubitemid 351832609)
48. Sprague RL, Kalachnik JE. Reliability, validity, and total score cutoff for the dyskinesia identification system: condensed user scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmocol Bull. 1991 ; 27: 51-58
49. Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. Am J Psychiatry. 1980 ; 137: 1163-1172
50. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry. 2005 ; 66: 1130-1133 (Pubitemid 41442279)
51. Tenback DE, van Harten PN, Slooff CJ, van Os J. Worsening of psychosis in schizophrenia is longitudinally associated with tardive dyskinesia in the European Schizophrenia Outpatient Health Outcomes study. Compr Psychiatry. 2007 ; 48: 436-440 (Pubitemid 47247438)
52. Van Os J, Fahy TA, Bebbington P, et al. The influence of life events on the subsequent course of psychotic illness. A prospective follow-up of the Camberwell Collaborative Psychosis Study. Psychol Med. 1994 ; 24: 503-513 (Pubitemid 24158862)
53. Van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk?. Acta Psychiatr Scand. 1997 ; 96: 206-216 (Pubitemid 27368460)
54. Waddington JL. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration: phenomenology, pathophysiology and putative relationship to tardive dyskinesia. Psychopharmocology. 1990 ; 101: 431-447 (Pubitemid 20220034)
55. Weaver T, Madden P, Charles V, et al. Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry. 2003 ; 183: 304-313 (Pubitemid 37243901)
56. Schedules for the Clinical Assessment in Neuropsychiatry (SCAN). Geneva: World Health Organization ; 1999 :
57. Wing JK, Cooper JE, Sartorius N Measurement and Classification of Psychiatric Symptoms. Cambridge: Cambridge University Press ; 1974 :
58. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003 ; 64: 663-667 (Pubitemid 36750143)